Skip to main content

Outcomes

Complex Evolution of RA Management and Outcomes FIRST is a Japanese longitudinal, real-world registry of rheumatoid arthritis (RA) management, and over the last 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain. https://t.co/Vqe70WAijN
Dr. John Cush @RheumNow( View Tweet )
Japan IORRA RA registry shows from 2011 to 2023, despite better Rx & control & less pred, Fractures went up in RA. From 2011 to 2023- DAS resmission 38 to 65%, bDMARD use 14 to 42%, GC use 38 to 22%, OP Rx 32 to 38%; But all FX incr 47 to 53/1000 Pys. https://t.co/cgz0Gkasai https://t.co/D2Uro7mEAT
Dr. John Cush @RheumNow( View Tweet )
Immune Checkpoint Inhib causing Myasthenia Gravis w/ poor outcomes - 16 ICI Rx pts (9 Lung CA, 7 other tumors) Dx w/ MG; 11 w/ overlap myositis. Mean onset @ 49d. All Rx wp steroids, 6 immunosuppressives, 5 plasma exchange; only 2 complete resp. 6 deaths re: MG complications https://t.co/re73lh2Xfs
Dr. John Cush @RheumNow( View Tweet )
Complex Evolution of RA Management and Outcomes FIRST is a Japanese longitudinal, real-world registry of rheumatoid arthritis (RA) management, and over the last 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain. https://t.co/TwDIf5MJqF
Dr. John Cush @RheumNow( View Tweet )
67 systemic sclerosis pts w/ mod-to-severe lower GI Sxs were Rx in phase 2, RDBPCT of placebo or fecal transplants at wks 0 and 2, with no signif change in GI sxs by week 12 (bloating or diarrhoea). https://t.co/vWq2c8d4Kn https://t.co/EZGgVYpxAl
Dr. John Cush @RheumNow( View Tweet )

Keys to Mastery (5.2.2025)

Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". This month's campaign on Lupus is sponsored by Aurinia.

Read Article

Secondary Benefits to SGLT2 Inhibitor Use in SLE

An emulation trial of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in systemic lupus erythematosus patients yielded a significantly reduced risk of several cardiorenal complications among patients with SLE and type 2 diabetes.

Read Article
45 southern African American SLE pts compared to multiethnic cSLE, AA pts had signif higher Dz activity & greater damage accrual. Their mean SLICC score was 8.4, SLEDAI 13, but was 7.4 @6 mos & 4,7 @1 yr. They traveled an avg distance 75 miles to see Rheum https://t.co/NMlT4uo8jn https://t.co/uG5ofMGE6O
Dr. John Cush @RheumNow( View Tweet )
2023 report from US NHANES study says #Gout affects 12.1 million in the USA. Gout prevalence incr from 3.6% in 2011/12 to 5.1% in 2017/2018. Recent increases do to doubling in Asian Americans from 3.3% to 6.6%. https://t.co/IBa3fOt83c https://t.co/aVHkg54IKp
Dr. John Cush @RheumNow( View Tweet )
Japan IORRA RA registry shows from 2011 to 2023, despite better Rx & control & less pred, Fractures went up in RA. From 2011 to 2023- DAS resmission 38 to 65%, bDMARD use 14 to 42%, GC use 38 to 22%, OP Rx 32 to 38%; But all FX incr 47 to 53/1000 Pys. https://t.co/cgz0Gkasai https://t.co/ziZr3BegDz
Dr. John Cush @RheumNow( View Tweet )

Contraception in SLE

Pregnancy in SLE gets a lot of press in the rheumatology literature, and deservedly so, since pregnancy risks can be markedly increased. It was not that many years ago that women with SLE were counseled to avoid pregnancy. As recently as 2004, the maternal mortality rate in SLE was 20-fold

Read Article
Immune Checkpoint Inhib causing Myasthenia Gravis w/ poor outcomes - 16 ICI Rx pts (9 Lung CA, 7 other tumors) Dx w/ MG; 11 w/ overlap myositis. Mean onset @ 49d. All Rx wp steroids, 6 immunosuppressives, 5 plasma exchange; only 2 complete resp. 6 deaths re: MG complications https://t.co/PUc6kIE7FW
Dr. John Cush @RheumNow( View Tweet )

Complex Evolution of RA Management and Outcomes

FIRST is a Japanese longitudinal, real-world registry of rheumatoid arthritis (RA) management, and over the last 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain.

Read Article

EULAR Guidelines on Reproductive Health

MedPage Today

Rheumatology patients considering or actually having babies can safely take most of the medications currently used to treat their conditions, according to an updated guideline from the European Alliance of Associations for Rheumatology (EULAR).

Read Article
Norwegian RevNatus Pregnancy study on 417 births in 350 women w/ axSpA: 86% (347) were breastfeeding @6wks, 70% @6mos, & 38% @12 mos. Non-breastfeeders more likely to have C-section (41 vs 20%), higher ASDAS-CRP (2.6 vs 2.2), CRP (5.3 vs 3.3), & VAS pain (41 vs 32) https://t.co/DI6owL5dof
Dr. John Cush @RheumNow( View Tweet )
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcomes. Infrapatellar fat pad (IPFP volume & signal) predicted future knee replacement & long-term damage. IPFP correlated w/ cartil. volume & BM lesions; Not Sxs. https://t.co/Xsju7JdEVE
Dr. John Cush @RheumNow( View Tweet )
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?

Dr. John Cush @RheumNow( View Tweet )

Gout pts No-Shows after ED: Study of 159 gout pts w/ gout flare & ED visit - only 56 (35%) had an outpatient visit addressing gout within 6 mos. Higher odds w/ being married (OR 2.66), no comorbidities (OR 3.86), colchicine use (OR 2.7), being older (OR 1.44) https://t.co/tAorjwf8xX
Dr. John Cush @RheumNow( View Tweet )

FDA Approves Rinvoq for Giant Cell Arteritis

Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication for upadacitinib in the U.S. for use in rheumatology,

Read Article
Looking for the latest updates on treatments and disparities for patients with systemic lupus erythematosus and lupus nephritis? Join us at AWIR 2025 to learn from Maria Dall’Era, MD, Jean S. Engleman Distinguished Professor of Medicine and Chief of the Division of https://t.co/QPyojkztCj
Association of Women in Rheumatology @AWIRGROUP( View Tweet )
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?

Dr. John Cush @RheumNow( View Tweet )

Norwegian RevNatus Pregnancy study on 417 births in 350 women w/ axSpA: 86% (347) were breastfeeding @6wks, 70% @6mos, & 38% @12 mos. Non-breastfeeders more likely to have C-section (41 vs 20%), higher ASDAS-CRP (2.6 vs 2.2), CRP (5.3 vs 3.3), & VAS pain (41 vs 32) https://t.co/GhLtLqT0iS
Dr. John Cush @RheumNow( View Tweet )
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcomes. Infrapatellar fat pad (IPFP volume & signal) predicted future knee replacement & long-term damage. IPFP correlated w/ cartil. volume & BM lesions; Not https://t.co/VrLfiSGWGA
Dr. John Cush @RheumNow( View Tweet )

Metformin Effective in Osteoarthritis

MedPage Today

The diabetes drug metformin provided overweight/obese patients with osteoarthritis (OA) of the knee with significantly greater pain relief than did placebo in a small randomized trial, researchers said.

Read Article

2024 Management of Familial Mediterranean Fever Recommendations

A EULAR/PReS combined task force has developed recommendations for the management of Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory disease worldwide. These evidence-based recommendations update the 2016 recommendations developed for rheumatologists and other HCPs

Read Article
×